Biopharmaceutical company AbbVie, Inc. (ABBV), while reporting weak profit in its first quarter despite revenue growth, on Wednesday raised outlook for fiscal 2026 adjusted earnings.
In pre-market activity, the shares were gaining around 2.3 percent, trading at $202.00.
For fiscal 2026, the company now expects adjusted earnings per share in a range of $14.08 to $14.28ious estimate of $13.96 to $14.16. The outlook includes an unfavorable impact of $0.41 per share related to acquired IPR&D and milestones expense.
In the first quarter, the company's bottom line came in at $695 million or $0.39 per share, compared with $1.28 billion or $0.72 per share last year.
Adjusted earnings were $4.71 billion or $2.65 per share for the period.
The company's revenue for the period rose 12.5 percent to $15.01 billion from $13.34 billion last year. Net revenues increased 10.3 percent on an operational basis.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.